Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner

The Johnson and Johnson Ad26.COV2.S single-dose vaccine represents an attractive option for coronavirus disease 2019 (COVID-19) vaccination in countries with limited resources. We examined the effect of prior infection with different SARS-CoV-2 variants on Ad26.COV2.S immunogenicity. We compared par...

Descripción completa

Detalles Bibliográficos
Autores principales: Keeton, Roanne, Richardson, Simone I., Moyo-Gwete, Thandeka, Hermanus, Tandile, Tincho, Marius B., Benede, Ntombi, Manamela, Nelia P., Baguma, Richard, Makhado, Zanele, Ngomti, Amkele, Motlou, Thopisang, Mennen, Mathilda, Chinhoyi, Lionel, Skelem, Sango, Maboreke, Hazel, Doolabh, Deelan, Iranzadeh, Arash, Otter, Ashley D., Brooks, Tim, Noursadeghi, Mahdad, Moon, James C., Grifoni, Alba, Weiskopf, Daniela, Sette, Alessandro, Blackburn, Jonathan, Hsiao, Nei-Yuan, Williamson, Carolyn, Riou, Catherine, Goga, Ameena, Garrett, Nigel, Bekker, Linda-Gail, Gray, Glenda, Ntusi, Ntobeko A.B., Moore, Penny L., Burgers, Wendy A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Short Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511649/
https://www.ncbi.nlm.nih.gov/pubmed/34688376
http://dx.doi.org/10.1016/j.chom.2021.10.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511649/
https://www.ncbi.nlm.nih.gov/pubmed/34688376
http://dx.doi.org/10.1016/j.chom.2021.10.003

Ejemplares similares